UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 83

Sortiert nach

Some studies of the excretion of diazotizable material after feeding 2-acetylaminofluorene to rats

Cancer research (Chicago, Ill.), 1950-08, Vol.10 (8), p.506-509

1950

Link zum Volltext

Verfügbarkeit prüfen

ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses

Cancer research (Chicago, Ill.), 2014-12, Vol.74 (23), p.6968-6979

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3067: OHM-581, a dual JAK2-BET inhibitor for the treatment of myelofibrosis and other hematologic malignancies

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3067-3067

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract P3-08-02: Withdrawn

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P3-P3-08-02

2019

Link zum Volltext

Verfügbarkeit prüfen

HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice

Cancer research (Chicago, Ill.), 2000-07, Vol.60 (13), p.3569-3576

2000

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-02-05: Apocrine morphology and LAR molecular subtype predict prognosis of TNBC patients with residual disease after neoadjuvant chemotherapy

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P4-P4-02-05

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD1-01: Trilaciclib (T), a CDK4/6 inhibitor, dosed with gemcitabine (G), carboplatin (C) in metastatic triple negative breast cancer (mTNBC) patients: Preliminary phase 2 results

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.PD1-01-PD1-01

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-03-09: A high specificity and sensitivity qPCR Assay for HER2, ER and PR gene expression in breast cancer patients

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P5-P5-03-09

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-05-02: Conditional inactivation of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) in the mouse mammary epithelium alters mammary gland development

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-05-02

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3012: Patient-derived models of rare cancers in the National Cancer Institute's patient-derived models repository

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.3012-3012

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3010: Single agent response comparisons in a large-scale, preclinical trial of rare cancer PDXs by the National Cancer Institute's patient-derived models repository

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.3010-3010

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 915: RNA processing signatures of normal versus malignant progenitor cell aging predict leukemia stem cell sensitivity to RNA splicing modulation

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.915-915

2016

Link zum Volltext

Verfügbarkeit prüfen

Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-fraumeni families

Cancer research (Chicago, Ill.), 1994-03, Vol.54 (5), p.1298-1304

1994

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-07-14: Rates of immune infiltration in patients with triple-negative breast cancers by molecular subtype and in patients with inflammatory and non-inflammatory breast cancers

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P1-P1-07-14

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT3-02-02: ENDEAR: A randomized international phase 3 study comparing the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy vs placebo with paclitaxel in patients with advanced diagnostic-positive triple-negative breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT3-02-02-OT3-02-02

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-02-08: Provista-002: A prospective, multi-center study to determine the effectiveness of a biomarker assay to distinguish benign from invasive breast cancer in women with BI-RADS 3, 4 and 5 imaging reports

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P1-P1-02-08

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1304: Brachytherapy dose heterogeneity primes response to immune checkpoint blockade to generate anti-tumor immunity

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.1304-1304

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3900: Genomic landscape of human cancer reveals dysregulated TGF-β signaling with prognostic significance

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3900-3900

2015

Link zum Volltext

Verfügbarkeit prüfen

P4-13-02: Hospice Utilization and End of Life Care in Metastatic Breast Cancer Patients at a Comprehensive Cancer Center

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P4-P4-13-02

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT3-3-01: A multicenter phase II study of docosahexaenoic acid (DHA) in triple negative breast cancer (TNBC) survivors

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.OT3-3-01-OT3-3-01

2013

Link zum Volltext

Verfügbarkeit prüfen

Ornithine decarboxylase overexpression leads to increased epithelial tumor invasiveness

Cancer research (Chicago, Ill.), 1997-06, Vol.57 (11), p.2104-2108

1997

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic radiation at a young age is linked to secondary thyroid cancer

Cancer research (Chicago, Ill.), 1991-06, Vol.51 (11), p.2885-2888

1991

Link zum Volltext

Verfügbarkeit prüfen

Abstract 156: Implications of LINE1 methylation for bladder cancer risk in women

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.156-156

2010

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant dose-dense doxorubicin-cyclophosphamide x 4 with or without bevacizumab is safe: no evidence of short-term changes in left ventricular ejection fraction

Cancer research (Chicago, Ill.), 2009-01, Vol.69 (2_Supplement), p.4102

2009

Link zum Volltext

Verfügbarkeit prüfen

SMS 201.995 inhibits in vitro and in vivo growth of human colon cancer

Cancer research (Chicago, Ill.), 1992-02, Vol.52 (4), p.917-923

1992

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 83

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieCancer Research

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(83)
Mit Volltextzugriff
(83)

Publikationsform

Artikel
(83)

Sprache

Englisch
(83)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Animals
(57)
Rats
(57)
Life Sciences & Biomedicine
(47)
Oncology
(47)
Science & Technology
(47)
Male
(33)
Carcinoma, Hepatocellular - Metabolism
(23)
Liver - Metabolism
(21)
Liver Neoplasms
(20)
Neoplasms, Experimental - Metabolism
(18)
Female
(17)
Carcinoma, Hepatocellular - Enzymology
(15)
Liver Neoplasms - Metabolism
(15)
Neoplasm Transplantation
(14)
Liver - Enzymology
(13)
Liver Neoplasms - Enzymology
(13)
Neoplasms, Experimental - Enzymology
(11)
Liver Regeneration
(10)
Old Medline
(10)
Carcinoma, Hepatocellular
(8)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Menü

Weitere Dienste

Einstellungen

Some studies of the excretion of diazotizable material after feeding 2-acetylaminofluorene to rats

ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses

Abstract 3067: OHM-581, a dual JAK2-BET inhibitor for the treatment of myelofibrosis and other hematologic malignancies

Abstract P3-08-02: Withdrawn

HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice

Abstract P4-02-05: Apocrine morphology and LAR molecular subtype predict prognosis of TNBC patients with residual disease after neoadjuvant chemotherapy

Abstract PD1-01: Trilaciclib (T), a CDK4/6 inhibitor, dosed with gemcitabine (G), carboplatin (C) in metastatic triple negative breast cancer (mTNBC) patients: Preliminary phase 2 results

Abstract P5-03-09: A high specificity and sensitivity qPCR Assay for HER2, ER and PR gene expression in breast cancer patients

Abstract P4-05-02: Conditional inactivation of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) in the mouse mammary epithelium alters mammary gland development

Abstract 3012: Patient-derived models of rare cancers in the National Cancer Institute's patient-derived models repository

Abstract 3010: Single agent response comparisons in a large-scale, preclinical trial of rare cancer PDXs by the National Cancer Institute's patient-derived models repository

Abstract 915: RNA processing signatures of normal versus malignant progenitor cell aging predict leukemia stem cell sensitivity to RNA splicing modulation

Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-fraumeni families

Abstract P1-07-14: Rates of immune infiltration in patients with triple-negative breast cancers by molecular subtype and in patients with inflammatory and non-inflammatory breast cancers

Abstract OT3-02-02: ENDEAR: A randomized international phase 3 study comparing the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy vs placebo with paclitaxel in patients with advanced diagnostic-positive triple-negative breast cancer

Abstract P1-02-08: Provista-002: A prospective, multi-center study to determine the effectiveness of a biomarker assay to distinguish benign from invasive breast cancer in women with BI-RADS 3, 4 and 5 imaging reports

Abstract 1304: Brachytherapy dose heterogeneity primes response to immune checkpoint blockade to generate anti-tumor immunity

Abstract 3900: Genomic landscape of human cancer reveals dysregulated TGF-β signaling with prognostic significance

P4-13-02: Hospice Utilization and End of Life Care in Metastatic Breast Cancer Patients at a Comprehensive Cancer Center

Abstract OT3-3-01: A multicenter phase II study of docosahexaenoic acid (DHA) in triple negative breast cancer (TNBC) survivors

Ornithine decarboxylase overexpression leads to increased epithelial tumor invasiveness

Therapeutic radiation at a young age is linked to secondary thyroid cancer

Abstract 156: Implications of LINE1 methylation for bladder cancer risk in women

Adjuvant dose-dense doxorubicin-cyclophosphamide x 4 with or without bevacizumab is safe: no evidence of short-term changes in left ventricular ejection fraction

SMS 201.995 inhibits in vitro and in vivo growth of human colon cancer

Aktive Filter

Suchergebnisse filtern